Seagen Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Seagen han disminuido a una tasa media anual de -28.6%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 22% al año.

Información clave

-28.6%

Tasa de crecimiento de los beneficios

-25.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	22.0%
Rentabilidad financiera	-29.4%
Margen neto	-32.6%
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Apr 17

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Mar 20

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Dec 09

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Oct 14

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Seagen. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:SGEN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 23	2,300	-750	922
30 Jun 23	2,162	-725	871
31 Mar 23	2,056	-649	883
31 Dec 22	1,962	-610	821
30 Sep 22	1,864	-637	816
30 Jun 22	1,778	-740	786
31 Mar 22	1,669	-690	731
31 Dec 21	1,574	-674	716
30 Sep 21	1,746	-333	664
30 Jun 21	2,383	597	611
31 Mar 21	2,273	661	571
31 Dec 20	2,176	614	534
30 Sep 20	1,864	472	491
30 Jun 20	1,016	-256	459
31 Mar 20	956	-314	416
31 Dec 19	917	-159	374
30 Sep 19	801	-304	338
30 Jun 19	758	-280	299
31 Mar 19	709	-124	275
31 Dec 18	655	-223	253
30 Sep 18	610	-162	222
30 Jun 18	576	-45	204
31 Mar 18	514	-177	187
31 Dec 17	482	-126	167
30 Sep 17	458	-121	160
30 Jun 17	429	-203	155
31 Mar 17	416	-180	148
31 Dec 16	418	-140	139
30 Sep 16	406	-110	132
30 Jun 16	384	-105	126
31 Mar 16	366	-119	123
31 Dec 15	337	-120	126
30 Sep 15	318	-122	122
30 Jun 15	309	-111	117
31 Mar 15	301	-82	112
31 Dec 14	287	-76	104
30 Sep 14	280	-65	100
30 Jun 14	275	-73	96
31 Mar 14	280	-63	94
31 Dec 13	269	-63	92
30 Sep 13	266	-57	90
30 Jun 13	245	-47	88
31 Mar 13	220	-58	84
31 Dec 12	211	-54	84

Ingresos de calidad: SGEN actualmente no es rentable.

Margen de beneficios creciente: SGEN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: SGEN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 28.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SGEN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: SGEN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: SGEN tiene una rentabilidad financiera negativa (-29.42%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Seagen Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Chief Technical Officer notifies of intention to sell stock

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Chief Technical Officer notifies of intention to sell stock

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Insider notifies of intention to sell stock

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Consensus EPS estimates fall by 12%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Chief Technical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 7.3% to US$216

Insider notifies of intention to sell stock

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Chief Financial Officer exercised options and sold US$8.8m worth of stock

Independent Director notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Price target increased by 7.7% to US$181

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 22%

Independent Director exercised options to buy US$1.4m worth of stock.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President of Research & Development notifies of intention to sell stock

President of Research & Development notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

President of Research & Development notifies of intention to sell stock

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Independent Director exercised options to buy US$1.1m worth of stock.

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Price target decreased to US$166

Chief Legal Officer exercised options to buy US$171k worth of stock.

Independent Director recently sold US$968k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Price target decreased to US$169

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen: A Stellar Portfolio Anchor

Seagen in licensing deal with Lava Therapeutics for cancer candidate

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen ticks lower as management suggests it could look at acquisitions

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Merck's talks with Seagen said to hit obstacle over price - report

Desglose de ingresos y gastos
Beta